Acadia Pharmaceuticals to Present at Canaccord Growth Conference
Event summary
- Acadia Pharmaceuticals will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026.
- The event is scheduled for 1:30 p.m. Eastern Time and will be webcast live on Acadia's website.
- An archived recording of the presentation will be available for approximately one month post-event.
The big picture
Acadia Pharmaceuticals' participation in the Canaccord Genuity Growth Conference underscores its focus on communicating with investors and analysts amid a competitive landscape in neurological treatments. The company's emphasis on its FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, along with its robust pipeline, positions it as a key player in addressing unmet medical needs.
What we're watching
- Pipeline Progress
- How Acadia's mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis will be addressed during the presentation.
- Market Positioning
- Whether Acadia can sustain its leadership in underserved neurological and rare disease communities with its current portfolio.
- Investor Sentiment
- The pace at which investor confidence may shift based on the insights shared during the fireside chat.
Related topics